Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy
UBL3 governs VEGFR inhibitor resistance by activating NOTCH signaling in renal cell carcinoma.
Diaoyi Tan, Yuzhong Ye, Daojia Miao, Chuanyi Zhao, Songming Wu, Jian Shi, Junkai Yang, Kanglin Fang, Feiyi Lu, Qingyang Lv, Jinshuo Gong, Hongmei Yang, Wen Xiao, Zhiyong Xiong, Xiaoping Zhang
Published: 202510.1016/j.drup.2025.101332
Abstract
BACKGROUND: Targeted therapy is the first-line treatment for patients with metastatic renal cell carcinoma (RCC), with vascular endothelial growth factor receptor inhibitors (VEGFRis) constituting the bulk of regimens used. Although the repertoire of…
Preview only. Read the full abstract at the source